US20160287576A1 - Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders - Google Patents

Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders Download PDF

Info

Publication number
US20160287576A1
US20160287576A1 US15/092,316 US201615092316A US2016287576A1 US 20160287576 A1 US20160287576 A1 US 20160287576A1 US 201615092316 A US201615092316 A US 201615092316A US 2016287576 A1 US2016287576 A1 US 2016287576A1
Authority
US
United States
Prior art keywords
mg
dextromethorphan
quinidine
day
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/092,316
Inventor
Gerald Yakatan
James Berg
Laura E. Pope
Richard A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US39666102P priority Critical
Priority to PCT/US2003/022303 priority patent/WO2004006930A1/en
Priority to US11/035,213 priority patent/US7659282B2/en
Priority to US12/699,408 priority patent/US20100137352A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30116047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160287576(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US13/679,256 priority patent/US20130072517A1/en
Priority to US14/059,058 priority patent/US20140045880A1/en
Priority to US14/298,571 priority patent/US20140288114A1/en
Priority to US14/680,275 priority patent/US20150209347A1/en
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Priority to US15/092,316 priority patent/US20160287576A1/en
Publication of US20160287576A1 publication Critical patent/US20160287576A1/en
Application status is Abandoned legal-status Critical

Links